Drug substitution in transplantation: A National Kidney Foundation white paper

Specific safeguards to guide the approval process and substitution practices for generic immunosuppressive agents are necessary for the effective delivery of patient care. Currently, the Food and Drug Administration (FDA) requires the demonstration of bioequivalence of generic drugs to innovator dru...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of kidney diseases 1999-02, Vol.33 (2), p.389-397
Hauptverfasser:	Sabatini, Sandra, Ferguson, Ronald M., Helderman, J.Harold, Hull, Alan R., Kirkpatrick, Beverly S., Barr, William H.
Format:	Artikel
Sprache:	eng
Schlagworte:	bioavailability bioequivalence Biological and medical sciences Biological Availability Dosage Forms Drugs, Generic - administration & dosage Drugs, Generic - pharmacokinetics generics Graft Rejection - prevention & control Humans Immunomodulators immunosuppressants Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - pharmacokinetics Kidney Transplantation Medical sciences Pharmacology. Drug treatments Societies, Medical Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system switchability Therapeutic Equivalency Transplantation United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!